Citations

Clear

3042 citation(s) found for "Kumar, S".

Clinical implication of centrosome amplification in plasma cell neoplasm
Ahmann, Greg, Henderson, Kim, Santana-Dávila, Rafael , Greipp, Philip R., Lacy, Martha Q. , Dispenzieri, Angela , Kumar, Shaji , Rajkumar, S. Vincent , Lust, John A., Kyle, Robert A. , Zeldenrust, Steven R., Hayman, Suzanne R. , Fonseca, Rafaël , Chng, Wee Joo , Henderson, Kimberly J., Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | December 23, 2005 | Volume: 107 | Issue: 9 | Pages: 3669-3675

10.1182/blood-2005-09-3810 | PMID 16373658 Get It

The mechanisms underlying aneuploidy in multiple myeloma (MM) are unclear. Centrosome amplification has been implicated as the cause of chromosomal instability in a variety of tumors and is a potential mechanism causing aneuploidy in MM. Using immunofluorescent (IF) staining, centrosome amplification was detected in 67% of monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS). We also investigated the gene expression of centrosome proteins. Overall, gene expression data correlated well with IF-detected centrosome amplification, allowing us to derive a gene expression-based centrosome index (CI) as a surrogate for centrosome amplification. Clinically, MM patients with high CI (> 4) are associated with poor prognostic genetic and clinical subtypes (chromosome 13 deletion, t(4; 14), t(14;16), and PCLI > 1%, P < .05) and are shown here to have short survival (11.1 months versus 39.1 months, P < .001). On multivariate regression, a high CI is an independent prognostic factor. Given that centrosome amplification is already observed in MGUS and probably integral to early chromosomal instability and myeloma genesis, and patients with more extensive centrosome amplification have shorter survival, the mechanisms leading to centrosome amplification should be investigated because these may offer new avenues for therapeutic intervention.
Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter
Dong, Xiangyang , Lütz, W, Schroeder, Tania M., Bachman, Lori A. , Kumar, Rajiv , Griffin, Matthew D. , Westendorf, Jennifer J. , Griffin, Matthew D , Kumar, Rajiv

Mayo Clinic

Proceedings of the National Academy of Sciences | October 26, 2005 | Volume: 102 | Issue: 44 | Pages: 16007-16012

10.1073/pnas.0506516102 | PMID 16239345 Get It

The NF-κB component RelB is essential for dendritic cell (DC) differentiation and maturation. The vitamin D receptor (VDR) is a nuclear receptor that mediates inhibition of DC maturation and transcriptional repression of relB after engagement of its ligand, 1α,25-dihydroxyvitamin D 3 , or related analogs (D 3 analogs). Ligand-dependent relB suppression was abolished by a histone deacetylase (HDAC) inhibitor. Constitutive association of VDR with the relB promoter was demonstrated in DCs by chromatin immunoprecipitation. Promoter binding by VDR was enhanced by ligand and reduced by LPS. Association of HDAC3 and HDAC1 with the relB VDR-binding site was observed, but only HDAC3 was reciprocally modulated by D 3 analog and LPS. Overexpression of HDAC3 caused relB promoter suppression, increased sensitivity to D 3 analog, and resistance to LPS. Depletion of HDAC3 attenuated relB suppression by D 3 analog. In vivo , D 3 analog resulted in reduced RelB in DCs from VDR WT mice but not VDR knockout mice. Other NF-lation of RelB and c-Rel in control animals. We conclude that vitamin D-regulated relB transcription in DCs is controlled by chromatin remodeling by means of recruitment of complexes including HDAC3.
Association of Gain and Loss of Weight before and after Menopause with Risk of Postmenopausal Breast Cancer in the Iowa Women's Health Study
Howell, Anthony , Vierkant, Robert A. , Kumar, Nagi B. , Cerhan, James R. , Kelemen, Linda E. , Folsom, Aaron R. , Sellers, Thomas A. , Harvie, Michelle , Cerhan, James R , Vierkant, Robert A

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 20, 2005 | Volume: 14 | Issue: 3 | Pages: 656-661

10.1158/1055-9965.epi-04-0001 | PMID 15767346 Get It

Abstract Obesity and adult weight gain are well-established risk factors for postmenopausal breast cancer. Although there are a few studies demonstrating the contribution of adult weight gain to breast cancer risk, whether weight gain during a critical time period is specifically associated with risk, or whether subsequent weight loss among women who have gained weight will reduce the excess risk, is not firmly established. We investigated the association of changes in weight (loss or gain in excess of 5% of body weight) using two risk factor models: (a) age 18 to 30 years and age 30 years to menopause and (b) age 30 years to menopause and after the menopause to the baseline study in 1986 on risk of postmenopausal breast cancer in a prospective cohort of 33,660 postmenopausal women in Iowa. Over 15 years of follow-up, 1,987 cases of breast cancer occurred. Data were analyzed using proportional hazards regression models adjusted for established breast cancer risk factors. The most frequently observed pattern of body weight over time was a consistent increase; these women were observed to have the highest rates of breast cancer and served as the reference category for all comparisons. The lowest-risk groups were (a) women who maintained or lost weight from age 18 to 30 years and then lost weight from age 30 years to menopause [risk ratio (RR), 0.36; 95% confidence interval (95% CI), 0.22-0.60] and (b) women who maintained or lost weight from age 30 years to menopause and then lost weight after the menopause (RR, 0.48; 95% CI, 0.22-0.65). Women who gained weight from age 30 years to menopause but then lost weight after the menopause experienced risk reductions (RR, 0.77; 95% CI, 0.64-0.92) although perhaps slightly smaller in magnitude than women who maintained their weight in both time intervals (RR, 0.63; 95% CI, 0.55-0.73). Women who gained weight from age 18 to 30 years and then lost weight from age 30 years to menopause had comparable risk reductions (RR, 0.61; 95% CI, 0.46-0.8) with women who maintained their weight in both time intervals (RR, 0.73; 95% CI, 0.64-0.84). Women who gained weight during the period from age 30 years to menopause but who had stable weight after menopause had rates similar to the reference group. These data suggest prevention of weight gain between age 18 years and menopause or weight loss and maintenance during these years reduces risk of postmenopausal breast cancer.
MULTI-INSTITUTIONAL VALIDATION STUDY OF NEURAL NETWORKS TO PREDICT DURATION OF STAY AFTER LAPAROSCOPIC RADICAL/SIMPLE OR PARTIAL NEPHRECTOMY
Parekattıl, Sıjo J. , Gill, Inderbir S. , Castle, Erik P., Burgess, Scott V., Walls, M., Thomas, Raju , Kumar, Udaya , Purifoy, Jody Ann, Ng, Christopher, Fuchs, Gerhard, Weise, Erik S., Winfield, Howard N., Lallas, Costas D. , Andrews, Paul E. , Kang, Young Mi , Gill, Inderbir S

Mayo Clinic

Journal of Urology | September 13, 2005 | Volume: 174 | Issue: 4 Part 1 | Pages: 1380-1384

10.1097/01.ju.0000173921.67597.e8 | PMID 16145442 Get It

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. Vincent , Hayman, Suzanne R. , Lacy, Martha Q. , Dispenzieri, Angela , Geyer, Susan M. , Kabat, Brian, Zeldenrust, Steven R., Kumar, Shaji , Greipp, Philip R., Fonseca, Rafaël , Lust, John A., Kyle, Robert A. , Russell, Stephen J. , Witzig, Thomas E. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | August 23, 2005 | Volume: 106 | Issue: 13 | Pages: 4050-4053

10.1182/blood-2005-07-2817 | PMID 16118317 Get It

We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/Dex) as initial therapy for myeloma. Thirtyfour patients were enrolled. Lenalidomide was given orally 25 mg daily on days 1 to 21 of a 28-day cycle. Dexamethasone was given orally 40 mg daily on days 1 to 4, 9 to 12, and 17 to 20 of each cycle. Objective response was defined as a decrease in serum monoclonal protein level by 50% or greater and a decrease in urine M protein level by at least 90% or to a level less than 200 mg/24 hours, confirmed by 2 consecutive determinations at least 4 weeks apart. Thirty-one of 34 patients achieved an objective response, including 2 (6%) achieving complete response (CR) and 11 (32%) meeting criteria for both very good partial response and near complete response, resulting in an overall objective response rate of 91%. Of the 3 remaining patients not achieving an objective response, 2 had minor response (MR) and one had stable disease. Fortyseven percent of patients experienced grade III or higher nonhematologic toxicity, most commonly fatigue (15%), muscle weakness (6%), anxiety (6%), pneumonitis (6%), and rash (6%). Rev/Dex is a highly active regimen with manageable side effects in the treatment of newly diagnosed myeloma.
Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance
Kumar, Shaji , Rajkumar, S. Vincent , Kyle, Robert A. , Lacy, Martha Q. , Dispenzieri, Angela , Fonseca, Rafaël , Lust, John A., Greipp, Philip R., Gertz, Morie A. , Witzig, Thomas E. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Journal of Clinical Oncology | August 18, 2005 | Volume: 23 | Issue: 24 | Pages: 5668-5674

10.1200/jco.2005.03.159 | PMID 16110026 Get It

Purpose Monoclonal gammopathy of undetermined significance (MGUS) progresses to multiple myeloma or another related plasma cell disorder (PCD) at a rate of approximately 1% per year. Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression. Patients and Methods Patients were eligible for this retrospective analysis if they were seen at the Mayo Clinic between 1984 and 1997, were diagnosed with MGUS, and had an analysis of the peripheral blood for circulating PCs by the slide-based immunofluorescence method. Patients were observed for progression to another PCD. Results Three hundred twenty-five patients were eligible and 63 (19%) had circulating PCs. Patients with circulating PCs were twice as likely (hazard ratio, 2.1) to experience progression to another PCD (most commonly myeloma), compared with those without circulating PCs (95% CI, 1.1 to 4.3; P = .03). In patients with circulating PCs, the median progression-free survival was 138 months compared with a median not yet reached for those without circulating PCs (P = .028). The median overall survival also was shorter for those with circulating PCs. Other factors with prognostic value were high levels of M protein and non–immunoglobulin G heavy-chain type. Conclusion The presence of circulating PCs, especially when combined with other known prognostic factors such as M protein concentration and immunoglobulin isotype, identify a group of individuals with MGUS at higher risk of progression to overt multiple myeloma.
Gene Expression Profiling of Orbital Adipose Tissue from Patients with Graves’ Ophthalmopathy: A Potential Role for Secreted Frizzled-Related Protein-1 in Orbital Adipogenesis
Kumar, Seema , Leontovich, Alexey A. , Coenen, Michael J., Bahn, Rebecca S.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | August 8, 2005 | Volume: 90 | Issue: 8 | Pages: 4730-4735

10.1210/jc.2004-2239 | PMID 15886250 Get It

Context: The signs and symptoms of Graves’ ophthalmopathy (GO) result from inflammation and increased volume of the orbital adipose tissues and extraocular muscles. Objective: Our objective was to identify differentially regulated genes that may be involved in stimulating the orbital adipose tissue expansion seen in GO. Design: Gene expression profiling was used to compare genes expressed in orbital adipose tissues from GO patients and normal individuals. Setting: The study took place at a private practice tertiary referral center. Patients: Orbital adipose tissues were collected at transantral orbital decompression surgery from 20 euthyroid patients undergoing this procedure for severe GO and at early autopsy from eight normal individuals having no evidence of thyroid or ocular disease. Results: Of the 12,686 genes analyzed, 25 known genes were increased in expression (&gt;4-fold) in GO orbital tissues, whereas 11 genes were decreased (&gt;4-fold). Up-regulated genes, confirmed by quantitative RT-PCR, included secreted frizzled-related protein-1 (sFRP-1; 18.5-fold) and several adipocyte-related genes, including peroxisome proliferator activated receptor-γ (44.1-fold) and adiponectin (25-fold). Treatment in vitro of GO orbital preadipocytes with recombinant sFRP-1 (100 nm) significantly increased adiponectin (2.0-fold; P &lt; 0.05), leptin (7-fold; P &lt; 0.002), and TSH receptor mRNA (13-fold; P &lt; 0.003) levels and enhanced Oil red-O staining in the cultures. Conclusions: These results support the concept that orbital adipogenesis is enhanced in GO and suggest that elevated levels of sFRP-1 in the GO orbit may be involved in stimulating this pathogenic process.
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
Kumar, Shaji , Hideshima, Teru , Roccaro, Aldo M. , Ishitsuka, Kenji , Yasui, Hiroshi , Shiraishi, Norihiko, Chauhan, Dharminder , Munshi, Nikhil C. , Green, Simon R. , Raje, Noopur , Anderson, Kenneth C. , Roccaro, Aldo M

Mayo Clinic

Blood | April 13, 2005 | Volume: 106 | Issue: 3 | Pages: 1042-1047

10.1182/blood-2005-01-0320 | PMID 15827128 Get It

AbstractCyclin-dependent kinase (CDK) inhibitors have the potential to induce cell-cycle arrest and apoptosis in cancer cells. Seliciclib (CYC202 or R-roscovitine) is a potent CDK inhibitor currently undergoing phase-2 clinical testing in lung and B-cell malignancies. Here we studied the in vitro cytotoxic activity of seliciclib against multiple myeloma (MM) cells. Our data demonstrate that seliciclib has potent cytotoxicity against MM cells that are both sensitive and resistant to conventional therapy as well as primary MM cells from patients. Cell-cycle and Western blot analysis confirmed apoptosis. Importantly, seliciclib triggered a rapid down-regulation of Mcl-1 transcription and protein expression independent of caspase cleavage. Adherence of MM cells to bone marrow stromal cells (BMSCs) induced increased Mcl-1 expression associated with signal transducer and activator of transcription 3 (STAT3) phosphorylation, which was inhibited in a time- and dose-dependent manner by seliciclib. Furthermore, seliciclib inhibited interleukin 6 (IL-6) transcription and secretion triggered by tumor cell binding to BMSCs. Up-regulation of Mcl-1 expression in cocultures was only partially blocked by neutralizing antibody to IL-6, suggesting alternative mechanisms of Mcl-1 modulation by seliciclib. Finally, combination studies of seliciclib with doxorubicin and bortezomib show in vitro synergism, providing the rationale for testing these drug combinations to improve patient outcome in MM.
Whole Urinary Proteins Coat Calcium Oxalate Monohydrate Crystals to Greatly Decrease Their Adhesion to Renal Cells
Farell, Gerard, Kumar, Vivek , Lieske, John C.

Mayo Clinic

Journal of Urology | August 25, 2004 | Volume: 170 | Issue: 1 | Pages: 221-225

10.1097/01.ju.0000059540.36463.9f | PMID 12796693 Get It

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Kumar, Shaji , Hideshima, Teru , Ishitsuka, Kenji , Chauhan, Dharminder , Mitsiades, Constantine S. , Podar, Klaus , Gouill, Steven Le , Richardson, Paul G. , Munshi, Nikhil C. , Stirling, David, Antin, Joseph H. , Raje, Noopur , Richardson, Paul Gerard Guy , Anderson, Kenneth C.

Mayo Clinic

Blood | August 20, 2004 | Volume: 104 | Issue: 13 | Pages: 4188-4193

10.1182/blood-2004-06-2281 | PMID 15319277 Get It

AbstractPrevious studies have demonstrated the in vitro and in vivo activity of CC-5013 (Revlimid), an immunomodulatory analog (IMiD) of thalidomide, in multiple myeloma (MM). In the present study, we have examined the anti-MM activity of rapamycin (Rapamune), a specific mTOR inhibitor, combined with CC-5013. Based on the Chou-Talalay method, combination indices of less than 1 were obtained for all dose ranges of CC-5013 when combined with rapamycin, suggesting strong synergism. Importantly, this combination was able to overcome drug resistance when tested against MM cell lines resistant to conventional chemotherapy. Moreover, the combination, but not rapamycin alone, was able to overcome the growth advantage conferred on MM cells by interleukin-6 (IL-6), insulin-like growth factor-1 (IGF-1), or adherence to bone marrow stromal cells (BMSCs). Combining rapamycin and CC-5013 induced apoptosis of MM cells. Differential signaling cascades, including the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3′-kinase/Akt kinase (PI3K/Akt) pathways, were targeted by these drugs individually and in combination, suggesting the molecular mechanism by which they interfere with MM growth and survival. These studies, therefore, provide the framework for clinical evaluation of mTOR inhibitors combined with IMiDs to improve patient outcome in MM.